

Emerging Treatment Options for RET-Driven Non-Small Cell Lung and Thyroid Cancers: Preparing Pharmacists to Optimize Patient Care

PowerPak Recorded Podcast

References

Ackermann CJ, Stock G, Tay R, et al. Targeted therapy for RET-rearranged non-small cell lung cancer: clinical development and future directions. *Onco Targets Ther.* 2019;12:7857–64.

Andreev-Drakhlin A, Roszik J, Subbiah V. The landscape of RET alterations from 56,970 adult patients with cancer: clinical implications. *J Clin Oncol.* 2019;37(15_suppl):3106.

Drilon A, Lin JJ, Filleron T, et al. Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers. *J Thorac Oncol.* 2018;13(10):1595–601.

Drilon A, Oxnard G, Wirth L, et al. PL02.08: Registrational results of LIBRETTO-001: a phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers. *J Thorac Oncol.* 2019;14(10 suppl):S6–7.

Gautschi O, Milia J, Filleron T, et al. Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry. *J Clin Oncol.* 2017;35(13):1403–10.

Kato S, Subbiah V, Marchlik E, et al. *RET* aberrations in diverse cancers: next-generation sequencing of 4,871 patients. *Clin Cancer Res.* 2017;23(8):1988–97.

Liu X, Shen T, Mooers BHM, et al. Drug resistance profiles of mutations in the RET kinase domain. *Br J Pharmacol.* 2018;175(17):3504–15.

Priya SR, Dravid CS, Digumarti R, Dandekar M. Targeted therapy for medullary thyroid cancer: a review. *Front Oncol.* 2017;7:238.

Rosenberg SM, Petrie KJ, Stanton AL, et al. Interventions to enhance adherence to oral antineoplastic agents: a scoping review. *J Natl Cancer Inst.* 2020;112(5):443–65.

Subbiah V, Hu MH, Gainor JF, et al. Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. *J Clin Oncol.* 2020;38(15_suppl):109.

Wirth LJ, Sherman E, Drilon A, et al. Registrational results of LIBRETTO-001: a phase 1/2 trial of selpercatinib (LOXO-292) in patients with RET-altered thyroid cancers. Presented at ESMO Congress 2019; September 27-October 1, 2019; Barcelona, Spain. Abstract LBA93.